Literature DB >> 6313275

Ranitidine kinetics in chronic renal impairment.

P Y Zech, N P Chau, N Pozet, M Labeeuw, A Hadj-Aissa.   

Abstract

The effects of moderate to severe renal impairment on kinetics of the H2-blocker ranitidine were investigated in 16 patients divided into two groups. Mean inulin clearance (ClIn) was 35 +/- 18.3 ml/min/1.73 m2 in group I and 7.4 +/- 3.5 ml/min/1.73 m2 in group II. Each patient received a single 150-mg oral dose of ranitidine. Values determined were maximum plasma concentration (MC) and time of occurrence, AUC, elimination t 1/2 (t 1/2 beta), total amount of unchanged ranitidine recovered in urine, and ranitidine renal clearance (ClR). MC values were higher and longer delayed than values reported in subjects with normal renal function. The t 1/2 beta was longer in group I and group II and correlated with the degree of renal impairment. The amount of ranitidine excreted within the first 24 hr decreased (18% of the dose in group I and 6% of the dose in group II), and ClR correlated strongly with ClIn, indicating that the observed changes in ranitidine kinetics are mainly related to changes in its renal excretion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313275     DOI: 10.1038/clpt.1983.230

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.

Authors:  M Morichau-Beauchant; G Houin; P Mavier; C Alexandre; D Dhumeaux
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

2.  Prediction of the Effects of Renal Impairment on Clearance for Organic Cation Drugs that Undergo Renal Secretion: A Simulation-Based Study.

Authors:  Kristin E Follman; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2018-02-28       Impact factor: 3.922

3.  The effect of renal function on the pharmacokinetics of ranitidine.

Authors:  J S Dixon; J M Borg-Costanzi; S J Langley; L F Lacey; S Toon
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; T Comstock; A Harford; F Eshelman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.